spacer
home > pmps > summer 2016 > the long arm of the regulator
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

The Long Arm of the Regulator

As the appetite grows in Western markets for healthy, natural foods and supplements that contribute to wellness, the opportunity for nutraceuticals is soaring. Public demand for superfoods and enriched functional sustenance is at an all-time high, while government and health providers are also promoting illness prevention through healthier lifestyles and dietary choices.

A recent report from Transparency Market Research suggests that the global nutraceuticals market will expand at a 7.30% compound annual rate between now and 2021 – from $182.60 billion in 2015 to $278.96 billion in five years, not least as a way of bringing chronic diseases under control (1).

The pharmaceutical industry, looking for new opportunities to dilute its reliance on expensive blockbuster drugs, is embracing nutraceuticals through acquisition or expansion of businesses to include a nutrition-oriented division. But where operations and staff have come from outside the pharma sector, there are likely to be gaps in those businesses’ understanding of the strict regulatory landscape they will be subject to.

Please see the full PDF for more details.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Peter Muller is Managing Director of Schlafender Hase (Americas). For the last 20 years, he has worked on software and process improvement projects with Fortune 500 companies from various industries: pharmaceutical, consumer goods, food, aerospace and defense. Peter has a wealth of experience working with international clients to define their organisation’s goals and help them leverage new technologies to achieve productivity gains, process improvements and cost savings.
spacer
Peter Muller
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Huge boom in Korean Pharma reported at CPhI Korea

Amsterdam, 19th September 2019: The recently-closed CPhI Korea – co-organised by Informa Markets and the Korea Pharmaceutical Traders Association (KPTA) – has seen a surge in growth across domestic and international pharma companies, as well as a sizable rise in overall attendees. As reported earlier this year in the provisional findings of the CPhI Pharma Index[1], Korea has seen a rapid growth in its international reputation (seeing its ‘overall competitiveness’ rise 14% in the last two years), which is now translating into a sizable growth in the market and at the event.
More info >>

White Papers

Driving ROI: The Case for Investing in Contract & Site Regulatory Document Management Services

DrugDev

With tight timelines and complicated regulatory documentation requirements, getting a clinical trial up and running quickly is easier said than done. Key milestones can be achieved only after the successful negotiation of clinical trial agreements and completion of essential regulatory documents. Many clinical trials are hindered by inefficient, labor-intensive processes. Prolonged, inefficient activation can hamper investigator satisfaction and, ultimately, have a negative bottom-line impact for sponsors and CROs. In addition, the Sunshine Act is heightening the importance of financial disclosure in clinical trials. Without a robust financial disclosure strategy, sponsors cannot ensure that physician self-reported financial disclosure data are aligned with the payment data being reported through the Sunshine Act, increasing financial and regulatory risk.
More info >>

 
Industry Events

2020 Avoca Quality and Innovation Summit

3-4 June 2020, Amsterdam, The Netherlands

The 2020 Avoca Quality and Innovation Summit will take place 3-4 June 2020, in Amsterdam, The Netherlands.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement